TickerTalks
Browse all tickers →
TickerTalks›$NKTR
NKNKTR

Nektar Therapeutics

$NKTR·$1.2B·Biotechnology·Healthcare
$61.69-0.5%YTD+46.0%1Y+113.0%
Mentions · last 7 days
2026-06-19: 34 posts2026-06-20: 20 posts2026-06-21: 7 posts2026-06-22: 51 posts2026-06-23: 9 posts2026-06-24: 15 posts2026-06-25: 24 posts162
Price updated 6m ago·X counts updated 20h ago
NKNKTR
$NKTRNektar Therapeutics
$61.69-0.55%162 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NKTR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventCooling offAI verdict · as of 2026-06-26

Catching its breath after a run — could pick back up or fade from here.

Clinical-stage biotech up 113% in twelve months with a fresh interim CFO and rising shareholder dissent — pipeline catalysts now have to deliver.

Nektar Therapeutics is a clinical-stage biotech with a focus on immuno-oncology and pain programs. The stock has more than doubled in twelve months, but the structural setup is mixed: shareholder dissent is elevated, the CFO has been replaced on an interim basis, and revenue is still tiny.

  • Revenue is essentially placeholder: Q1 revenue grew 3.8% YoY to just $10.9M with operating margin -352% — the equity is a binary clinical bet, not a commercial story.
  • The Annual Meeting signal is the loudest governance flag: director Howard Robin was re-elected with 27% dissent — that's an unusually high withhold rate signaling shareholder pushback on board composition.
  • Interim CFO Linda Rubinstein (Form 3 May 26) replacing the prior CFO during pipeline-investment phase adds execution uncertainty — leadership transitions in clinical-stage biotechs matter for credibility.
  • Insider tape leans selling: director Howard Robin sold $1.2M across two blocks and officer Jonathan Zalevsky sold $336K — meaningful relative to the $1.2B market cap.
  • Earnings beats have actually been positive: -5%, +36%, +35%, +6% — modest variability but trending positive, which is consistent with the T12M run.

If Aug 6 Q2 brings a meaningful clinical-pipeline update plus a permanent CFO with biotech-finance credibility, the multi-bagger thesis stays intact. Continued senior insider selling or any pipeline-trial setback would extend the cooling toward the prior $40 range.

What to watch: Aug 6 Q2 — meaningful clinical-pipeline update plus a permanent CFO with biotech-finance credibility is the win condition; continued senior insider selling or any pipeline-trial setback extends the cooling toward the prior $40 range.

On the calendar: 2026-08-06 — Q2 earnings

Read the AI verdict + X sentiment for $NKTR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NKTR.

Biotechnology · Healthcare

GLP-1 pipeline competition is the dominant structural driver — the ADA conference crystallized oral formulations, dual agonists, and differentiated mechanisms competing for a potential $150B obesity market by 2030. QURE's FDA accelerated approval for AMT-130 (Huntington's disease) this week confirms gene therapy regulatory momentum is still flowing capital to non-GLP-1 precision medicine.

Top industry ETF

$IBBiShares Biotechnology ETF
+8.3%YTD
+45.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-17.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-225%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-16.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
21.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-87.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-1.82$-1.74-4.6%
Q4 2025Mar 12, 2026$-1.78$-2.76+35.5%
Q3 2025Nov 6, 2025$-1.85$-2.85+35.1%
Q2 2025Aug 7, 2025$-2.95$-3.13+5.8%
Next earningsThu, Aug 6·consensus EPS $-2.05

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$10.9M+3.8%98.6%-352%$-1.82$-44.3M
Q4 FY25$21.8M-25.3%100%-87.5%$-1.78$-65.0M
Q3 FY25$11.8M-51.1%98.3%-267%$-1.87$-48.9M
Q2 FY25$11.2M-52.4%100%-324%$-2.95$-45.8M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$41.2M$40.4M – $41.9M-$9.06-$10.57 – -$7.339
FY27$36.9M$20.0M – $41.8M-$11.07-$13.23 – -$6.489
FY28$52.4M$31.2M – $58.3M-$11.40-$14.32 – -$7.339
FY29$94.8M$56.4M – $105.5M-$10.61-$12.17 – -$5.034
FY30$199.2M$118.6M – $221.7M-$8.02-$9.20 – -$3.804

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.47%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-14.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+1.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 18.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today5.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.155-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 17Howard W RobinCEO10.0K sh$612KSellJun 16Howard W RobinCEO10.0K sh$603KSellJun 15Jonathan ZalevskyChief R&D Officer5.5K sh$336KSellMay 19Jonathan ZalevskyChief R&D Officer199 sh$13KSellMay 19Howard W RobinCEO444 sh$29KSellFeb 18Jonathan ZalevskyChief R&D Officer180 sh$13KSellFeb 18Howard W RobinCEO423 sh$31KSellJan 20Jonathan ZalevskyChief R&D Officer3.9K sh$138K

See when $NKTR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 58-K — Item 5.07: Shareholder vote
AI summary

Nektar Therapeutics (NKTR) reported its June 4, 2026 Annual Meeting results. Howard W. Robin was elected to the board (Class III, until 2029) with 13,164,879 votes for vs. 4,975,288 against — a notable 27% dissent rate. The 2017 Performance Incentive Plan was amended to add 3,000,000 shares authorized for issuance (approved 13.16M for / 4.90M against). Ernst & Young LLP was ratified as auditor. The ~27% against vote for the sole director election is a governance flag; the 3M additional share authorization is modestly dilutive for a small-cap biotech.

3New insider — initial holdingsMay 263
AI summary

Linda M. Rubinstein filed a Form 3 as Interim CFO of Nektar Therapeutics (NKTR) on May 26, 2026, triggered by her appointment on May 15, 2026. Rubinstein is based at Nektar's San Francisco headquarters. The filing discloses no securities beneficially owned. Routine Form 3 for a newly appointed interim CFO — the 'interim' designation signals an ongoing CFO search at this clinical-stage biotech.

424B5Prospectus supplement (offering)May 8424B5
AI summary

Nektar Therapeutics (NKTR) filed a 424B5 prospectus supplement on May 8, 2026 for an ATM offering of up to $150M in common stock via Guggenheim Securities and H.C. Wainwright as sales agents (3.0% commission). The last reported sale price was $85.09 on May 6, 2026. No shares had been sold as of filing. The $150M ATM program is a meaningful potential dilution for a clinical-stage biotech, indicating management is building flexible capital reserves ahead of upcoming clinical milestones.

8-KMaterial agreementMay 88-K — Item 1.01: Material agreement · Item 5.02: Officer or director change
AI summary

Nektar Therapeutics (NKTR) entered an Equity Distribution Agreement on May 8, 2026 with Guggenheim Securities and H.C. Wainwright for an ATM offering of up to $150M in common stock (3.0% commission), registered under Nektar's November 2025 S-3 shelf. No obligation to sell; the program provides an on-demand capital raising mechanism through Nasdaq. A material liquidity option for a biotech dependent on external funding, complementing the concurrent 424B5 filing.

8-KMaterial agreementApr 238-K — Item 1.01: Material agreement · Item 8.01: Other event
424B5Prospectus supplement (offering)Apr 23424B5
424B5Prospectus supplement (offering)Apr 20424B5
8-KPress release / Reg FDApr 208-K — Item 7.01: Press release / Reg FD
+ 21 other (7 13Gs · 5 8-Ks · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Yearfool.com·2d ago3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal247wallst.com·3d agoNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com·23d agoNektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New Yorkprnewswire.com·30d agoPatient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Sharesfool.com·41d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$DFTX$APGE$IBRX$QURE$PRAX$INSM$REPL
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport